134 related articles for article (PubMed ID: 38638098)
1. The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs.
Sabale U; Karamousouli E; Popovic L; Krasznai ZT; Harrop D; Meiwald A; Hughes R; Weston G; Bencina G
J Med Econ; 2024 Apr; 27(sup2):1-8. PubMed ID: 38638098
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs.
Bencina G; Chami N; Hughes R; Weston G; Baxter C; Maciejczyk A; Popovic L; Karamousouli E; Salomonsson S
J Med Econ; 2023; 26(1):254-261. PubMed ID: 36756852
[TBL] [Abstract][Full Text] [Related]
3. Lost productivity due to head and neck cancer mortality in Hungary, Poland, and Romania.
Bencina G; Chami N; Hughes R; Weston G; Golusiński PJ
J Cancer Policy; 2022 Dec; 34():100366. PubMed ID: 36244644
[TBL] [Abstract][Full Text] [Related]
4. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.
Bray F; Lortet-Tieulent J; Znaor A; Brotons M; Poljak M; Arbyn M
Vaccine; 2013 Dec; 31 Suppl 7():H32-45. PubMed ID: 24332296
[TBL] [Abstract][Full Text] [Related]
5. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003.
Ekwueme DU; Chesson HW; Zhang KB; Balamurugan A
Cancer; 2008 Nov; 113(10 Suppl):2936-45. PubMed ID: 18980277
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
7. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
8. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
10. Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States.
Priyadarshini M; Prabhu VS; Snedecor SJ; Corman S; Kuter BJ; Nwankwo C; Chirovsky D; Myers E
Front Public Health; 2020; 8():624092. PubMed ID: 33665180
[No Abstract] [Full Text] [Related]
11. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review.
Préaud E; Largeron N
J Med Econ; 2013; 16(6):763-76. PubMed ID: 23565814
[TBL] [Abstract][Full Text] [Related]
12. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Cervical Cancer in Bulgaria.
Lebanova H; Stoev S; Naseva E; Getova V; Wang W; Sabale U; Petrova E
Int J Environ Res Public Health; 2023 Feb; 20(3):. PubMed ID: 36768109
[TBL] [Abstract][Full Text] [Related]
14. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe.
Hanly P; Soerjomataram I; Sharp L
Int J Cancer; 2015 Feb; 136(4):E136-45. PubMed ID: 25066804
[TBL] [Abstract][Full Text] [Related]
15. Current status of human papillomavirus vaccination implementation in central and eastern Europe.
Seme K; Maver PJ; Korać T; Canton A; Částková J; Dimitrov G; Filippova I; Hudecová H; Iljazović E; Kaić B; Kesić V; Kuprevičienė N; Laušević D; Molnár Z; Perevoščikovs J; Spaczyński M; Stefanova V; Učakar V; Poljak M
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(1):21-5. PubMed ID: 23674181
[TBL] [Abstract][Full Text] [Related]
16. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
17. Burden of varicella in Central and Eastern Europe: findings from a systematic literature review.
Mészner Z; Wysocki J; Richter D; Zavadska D; Ivaskeviciene I; Usonis V; Pokorn M; Mangarov A; Jancoriene L; Man SC; Kristufkova Z; Jesenak M; Tešović G; Pluta J; Wolfson LJ
Expert Rev Vaccines; 2019 Mar; 18(3):281-293. PubMed ID: 30810402
[TBL] [Abstract][Full Text] [Related]
18. Global burden and economic impact of vaccine-preventable cancer mortality.
Bencina G; Oliver E; Meiwald A; Hughes R; Morais E; Weston G; Sundström K
J Med Econ; 2024 May; ():1-17. PubMed ID: 38721643
[TBL] [Abstract][Full Text] [Related]
19. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
